サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1552737

PCSK9阻害薬の世界市場：産業分析、規模、シェア、成長、動向、予測、2024-2034年

PCSK9 Inhibitor Market (Drug Type: Alirocumab, Evolocumab, Inclisiran, and Tafolecimab; and Modality: Fully-humanized Monoclonal Antibodies and siRNA) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

出版日
ページ情報
英文 134 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.87円
PCSK9阻害薬の世界市場：産業分析、規模、シェア、成長、動向、予測、2024-2034年
出版日: 2024年07月17日
発行: Transparency Market Research
ページ情報: 英文 134 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

PCSK9阻害薬市場- 調査範囲

TMRの調査レポート「PCSK9阻害薬の世界市場」は、2024年から2034年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2024年を基準年、2034年を予測年として、2018年から2034年までの世界のPCSK9阻害薬市場の収益と予測を提供しています。また、2024年から2034年までの世界のPCSK9阻害薬市場の複合年間成長率（CAGR %）も掲載しています。

本レポートは広範な調査を経て作成されています。1次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、主要企業の製品資料、アニュアルレポート、プレスリリース、関連資料などを参照し、PCSK9阻害薬市場を推察しました。

市場スナップショット
2023年の市場規模 17億米ドル
2034年の市場規模 93億米ドル
CAGR 16.9%

当レポートでは、世界のPCSK9阻害薬市場の競合情勢について調査しています。世界のPCSK9阻害薬市場で事業を展開する主要企業が特定され、各企業が様々な属性でプロファイルされています。企業概要、財務状況、最近の動向、SWOTなどが、本レポートで紹介されている世界のPCSK9阻害薬市場におけるプレイヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界の市場分析と予測、2020-2034年

第5章 主要洞察

  • パイプライン分析
  • 主要製品/ブランド分析
  • 主要M&A
  • COVID-19による産業への影響

第6章 世界の市場分析と予測：薬剤の種類別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：薬剤の種類別、2020-2034年
    • アリロクマブ
    • エボロクマブ
    • インクリシラン
    • タフォレシマブ
  • 市場の魅力：薬剤の種類別

第7章 世界の市場分析と予測：モダリティ別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：モダリティ別、2020-2034年
    • 完全ヒト化モノクローナル抗体
    • siRNA
  • 市場の魅力：モダリティ別

第8章 世界の市場分析と予測：適応症別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：適応症別、2020-2034年
    • 原発性高脂血症
    • 家族性高コレステロール血症
    • その他
  • 市場の魅力：適応症別

第9章 世界の市場分析と予測：流通チャネル別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：流通チャネル別、2020-2034年
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 市場の魅力：流通チャネル別

第10章 世界の市場分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2020-2034年
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力：地域別

第11章 北米の市場分析と予測

第12章 欧州の市場分析と予測

第13章 アジア太平洋地域の市場分析と予測

第14章 ラテンアメリカの市場分析と予測

第15章 中東・アフリカの市場分析と予測

第16章 競合情勢

  • 市場企業-競合マトリックス（企業階層と規模別）
  • 市場シェア分析：企業別（2023）
  • 企業プロファイル
    • Novartis AG
    • Regeneron Pharmaceuticals
    • Amgen Inc.
    • Innovent Bio
    • LIB Therapeutics
    • Shanghai Junshi Biosciences Co., Ltd.
    • Merck & Co., Inc.
    • AstraZeneca plc
図表

List of Tables

  • Table 01: Global PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
  • Table 02: Global PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Modality, 2020-2034
  • Table 03: Global PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 04: Global PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Indication, 2020-2034
  • Table 05: Global PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Region, 2020-2034
  • Table 06: North America PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Country, 2020-2034
  • Table 07: North America PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
  • Table 08: North America PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Modality, 2020-2034
  • Table 9: North America PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Indication, 2020-2034
  • Table 10: North America PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 11: Europe PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 12: Europe PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
  • Table 13: Europe PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Modality, 2020-2034
  • Table 14: Europe PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Indication, 2020-2034
  • Table 15: Europe PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 16: Asia Pacific PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 17: Asia Pacific PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
  • Table 18: Asia Pacific PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Modality, 2020-2034
  • Table 19: Asia Pacific PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Indication, 2020-2034
  • Table 20: Asia Pacific PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 21: Latin America PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 22: Latin America PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
  • Table 23: Latin America PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Modality, 2020-2034
  • Table 24: Latin America PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Indication, 2020-2034
  • Table 25: Latin America PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 26: Middle East & Africa PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 27: Middle East & Africa PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
  • Table 28: Middle East & Africa PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Modality, 2020-2034
  • Table 29: Middle East & Africa PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Indication, 2020-2034
  • Table 30: Middle East & Africa PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

List of Figures

  • Figure 01: Global PCSK9 Inhibitors Market Size (US$ Bn), by Region, 2023 and 2034
  • Figure 02: Global PCSK9 Inhibitors Market Revenue (US$ Bn), by Drug Type, 2023
  • Figure 03: Global PCSK9 Inhibitors Market Value Share, by Drug Type, 2023
  • Figure 04: Global PCSK9 Inhibitors Market Revenue (US$ Bn), by Modality, 2023
  • Figure 05: Global PCSK9 Inhibitors Market Value Share, by Modality, 2023
  • Figure 06: Global PCSK9 Inhibitors Market Revenue (US$ Bn), by Indication, 2023
  • Figure 07: Global PCSK9 Inhibitors Market Value Share, by Indication, 2023
  • Figure 08: Global PCSK9 Inhibitors Market Revenue (US$ Bn), by Distribution Channel, 2023
  • Figure 09: Global PCSK9 Inhibitors Market Value Share, by Distribution Channel, 2023
  • Figure 10: Global PCSK9 Inhibitors Market Value Share, by Region, 2023
  • Figure 11: Global PCSK9 Inhibitors Market Value (US$ Bn) Forecast, 2020-2034
  • Figure 12: Global PCSK9 Inhibitors Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 13: Global PCSK9 Inhibitors Market Attractiveness Analysis, by Drug Type, 2024-2034
  • Figure 14: Global PCSK9 Inhibitors Market Value Share Analysis, by Modality, 2023 and 2034
  • Figure 15: Global PCSK9 Inhibitors Market Attractiveness Analysis, by Modality, 2024-2034
  • Figure 16: Global PCSK9 Inhibitors Market Value Share Analysis, by Indication, 2023 and 2034
  • Figure 17: Global PCSK9 Inhibitors Market Attractiveness Analysis, by Indication, 2024-2034
  • Figure 18: Global PCSK9 Inhibitors Market Revenue (US$ Bn), by Distribution Channel, 2023
  • Figure 19: Global PCSK9 Inhibitors Market Value Share, by Distribution Channel, 2023
  • Figure 20: Global PCSK9 Inhibitors Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 21: Global PCSK9 Inhibitors Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 22: North America PCSK9 Inhibitors Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 23: North America PCSK9 Inhibitors Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 24: North America PCSK9 Inhibitors Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 25: North America PCSK9 Inhibitors Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 26: North America PCSK9 Inhibitors Market Value Share Analysis, by Modality, 2023 and 2034
  • Figure 27: North America PCSK9 Inhibitors Market Value Share Analysis, by Indication, 2023 and 2034
  • Figure 28: North America PCSK9 Inhibitors Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 29: North America PCSK9 Inhibitors Market Attractiveness Analysis, by Drug Type, 2024-2034
  • Figure 30: North America PCSK9 Inhibitors Market Attractiveness Analysis, by Modality, 2024-2034
  • Figure 31: North America PCSK9 Inhibitors Market Attractiveness Analysis, by Indication, 2024-2034
  • Figure 32: North America PCSK9 Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 33: Europe PCSK9 Inhibitors Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 34: Europe PCSK9 Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 35: Europe PCSK9 Inhibitors Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 36: Europe PCSK9 Inhibitors Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 37: Europe PCSK9 Inhibitors Market Value Share Analysis, by Modality, 2023 and 2034
  • Figure 38: Europe PCSK9 Inhibitors Market Value Share Analysis, by Indication, 2023 and 2034
  • Figure 39: Europe PCSK9 Inhibitors Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 40: Europe PCSK9 Inhibitors Market Attractiveness Analysis, by Drug Type, 2024-2034
  • Figure 41: Europe PCSK9 Inhibitors Market Attractiveness Analysis, by Modality, 2024-2034
  • Figure 42: Europe PCSK9 Inhibitors Market Attractiveness Analysis, by Indication, 2024-2034
  • Figure 43: Europe PCSK9 Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 44: Asia Pacific PCSK9 Inhibitors Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 45: Asia Pacific PCSK9 Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 46: Asia Pacific PCSK9 Inhibitors Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 47: Asia Pacific PCSK9 Inhibitors Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 48: Asia Pacific PCSK9 Inhibitors Market Value Share Analysis, by Modality, 2023 and 2034
  • Figure 49: Asia Pacific PCSK9 Inhibitors Market Value Share Analysis, by Indication, 2023 and 2034
  • Figure 50: Asia Pacific PCSK9 Inhibitors Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 51: Asia Pacific PCSK9 Inhibitors Market Attractiveness Analysis, by Drug Type, 2024-2034
  • Figure 52: Asia Pacific PCSK9 Inhibitors Market Attractiveness Analysis, by Modality, 2024-2034
  • Figure 53: Asia Pacific PCSK9 Inhibitors Market Attractiveness Analysis, by Indication, 2024-2034
  • Figure 54: Asia Pacific PCSK9 Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2023-2034
  • Figure 55: Latin America PCSK9 Inhibitors Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 56: Latin America PCSK9 Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 57: Latin America PCSK9 Inhibitors Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 58: Latin America PCSK9 Inhibitors Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 59: Latin America PCSK9 Inhibitors Market Value Share Analysis, by Modality, 2023 and 2034
  • Figure 60: Latin America PCSK9 Inhibitors Market Value Share Analysis, by Indication, 2023 and 2034
  • Figure 61: Latin America PCSK9 Inhibitors Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 62: Latin America PCSK9 Inhibitors Market Attractiveness Analysis, by Drug Type, 2024-2034
  • Figure 63: Latin America PCSK9 Inhibitors Market Attractiveness Analysis, by Modality, 2024-2034
  • Figure 64: Latin America PCSK9 Inhibitors Market Attractiveness Analysis, by Indication, 2024-2034
  • Figure 65: Latin America PCSK9 Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 66: Middle East & Africa PCSK9 Inhibitors Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 67: Middle East & Africa PCSK9 Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 68: Middle East & Africa PCSK9 Inhibitors Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 69: Middle East & Africa PCSK9 Inhibitors Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 70: Middle East & Africa PCSK9 Inhibitors Market Value Share Analysis, by Modality, 2023 and 2034
  • Figure 71: Middle East & Africa PCSK9 Inhibitors Market Value Share Analysis, by Indication, 2023 and 2034
  • Figure 72: Middle East & Africa PCSK9 Inhibitors Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 73: Middle East & Africa PCSK9 Inhibitors Market Attractiveness Analysis, by Drug Type, 2024-2034
  • Figure 74: Middle East & Africa PCSK9 Inhibitors Market Attractiveness Analysis, by Modality, 2024-2034
  • Figure 75: Middle East & Africa PCSK9 Inhibitors Market Attractiveness Analysis, by Indication, 2024-2034
  • Figure 76: Middle East & Africa PCSK9 Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2024-2034
目次
Product Code: TMRGL83528

PCSK9 Inhibitor Market - Scope of Report

TMR's report on the global PCSK9 inhibitor market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global PCSK9 inhibitor market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global PCSK9 inhibitor market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the PCSK9 inhibitor market.

Market Snapshot
Market Value in 2023US$ 1.7 Bn
Market Value in 2034US$ 9.3 Bn
CAGR16.9%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global PCSK9 inhibitor market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global PCSK9 inhibitor market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global PCSK9 inhibitor market.

The report delves into the competitive landscape of the global PCSK9 inhibitor market. Key players operating in the global PCSK9 inhibitor market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global PCSK9 inhibitor market profiled in this report.

Key Questions Answered in Global PCSK9 inhibitor Market Report:

  • What is the sales/revenue generated by PCSK9 inhibitor across all regions during the forecast period?
  • What are the opportunities in the global PCSK9 inhibitor market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

PCSK9 Inhibitor Market - Research Objectives and Research Approach

The comprehensive report on the global PCSK9 inhibitor market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global PCSK9 inhibitor market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global PCSK9 inhibitor market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global PCSK9 Inhibitors Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global PCSK9 Inhibitors Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global PCSK9 Inhibitors Market Analysis and Forecast, by Drug Type

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Type, 2020-2034
    • 6.3.1. Alirocumab
    • 6.3.2. Evolocumab
    • 6.3.3. Inclisiran
    • 6.3.4. Tafolecimab
  • 6.4. Market Attractiveness, by Drug Type

7. Global PCSK9 Inhibitors Market Analysis and Forecast, by Modality

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Modality, 2020-2034
    • 7.3.1. Fully-humanized Monoclonal Antibodies
    • 7.3.2. siRNA
  • 7.4. Market Attractiveness, by Modality

8. Global PCSK9 Inhibitors Market Analysis and Forecast, by Indication

  • 8.1. Introduction and Definitions
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Indication, 2020-2034
    • 8.3.1. Primary Hyperlipidemia
    • 8.3.2. Familial Hyper Cholesterolemia
    • 8.3.3. Other Cardiovascular Disorders
  • 8.4. Market Attractiveness, by Indication

9. Global PCSK9 Inhibitors Market Analysis and Forecast, by Distribution Channel

  • 9.1. Introduction and Definitions
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by Distribution Channel, 2020-2034
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies
  • 9.4. Market Attractiveness, by Distribution Channel

10. Global PCSK9 Inhibitors Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region, 2020-2034
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness, by Region

11. North America PCSK9 Inhibitors Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Type, 2020-2034
    • 11.2.1. Alirocumab
    • 11.2.2. Evolocumab
    • 11.2.3. Inclisiran
    • 11.2.4. Tafolecimab
  • 11.3. Market Attractiveness, by Drug Type
  • 11.4. Market Value Forecast, by Modality, 2020-2034
    • 11.4.1. Fully-humanized Monoclonal Antibodies
    • 11.4.2. siRNA
  • 11.5. Market Attractiveness, by Modality
  • 11.6. Market Value Forecast, by Indication, 2020-2034
    • 11.6.1. Primary Hyperlipidemia
    • 11.6.2. Familial Hyper Cholesterolemia
    • 11.6.3. Other Cardiovascular Disorders
  • 11.7. Market Attractiveness, by Indication
  • 11.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 11.8.1. Hospital Pharmacies
    • 11.8.2. Retail Pharmacies
    • 11.8.3. Online Pharmacies
  • 11.9. Market Attractiveness, by Distribution Channel
  • 11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.10.1. U.S.
    • 11.10.2. Canada
  • 11.11. Market Attractiveness Analysis
    • 11.11.1. By Drug Type
    • 11.11.2. By Modality
    • 11.11.3. By Indication
    • 11.11.4. By Distribution Channel
    • 11.11.5. By Country

12. Europe PCSK9 Inhibitors Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Type, 2020-2034
    • 12.2.1. Alirocumab
    • 12.2.2. Evolocumab
    • 12.2.3. Inclisiran
    • 12.2.4. Tafolecimab
  • 12.3. Market Attractiveness, by Drug Type
  • 12.4. Market Value Forecast, by Modality, 2020-2034
    • 12.4.1. Fully-humanized Monoclonal Antibodies
    • 12.4.2. siRNA
  • 12.5. Market Attractiveness, by Modality
  • 12.6. Market Value Forecast, by Indication, 2020-2034
    • 12.6.1. Primary Hyperlipidemia
    • 12.6.2. Familial Hyper Cholesterolemia
    • 12.6.3. Other Cardiovascular Disorders
  • 12.7. Market Attractiveness, by Indication
  • 12.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 12.8.1. Hospital Pharmacies
    • 12.8.2. Retail Pharmacies
    • 12.8.3. Online Pharmacies
  • 12.9. Market Attractiveness, by Distribution Channel
  • 12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.10.1. Germany
    • 12.10.2. U.K.
    • 12.10.3. France
    • 12.10.4. Italy
    • 12.10.5. Spain
    • 12.10.6. Rest of Europe
  • 12.11. Market Attractiveness Analysis
    • 12.11.1. By Drug Type
    • 12.11.2. By Modality
    • 12.11.3. By Indication
    • 12.11.4. By Distribution Channel
    • 12.11.5. By Country/Sub-region

13. Asia Pacific PCSK9 Inhibitors Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Type, 2020-2034
    • 13.2.1. Alirocumab
    • 13.2.2. Evolocumab
    • 13.2.3. Inclisiran
    • 13.2.4. Tafolecimab
  • 13.3. Market Attractiveness, by Drug Type
  • 13.4. Market Value Forecast, by Modality, 2020-2034
    • 13.4.1. Fully-humanized Monoclonal Antibodies
    • 13.4.2. siRNA
  • 13.5. Market Attractiveness, by Modality
  • 13.6. Market Value Forecast, by Indication, 2020-2034
    • 13.6.1. Primary Hyperlipidemia
    • 13.6.2. Familial Hyper Cholesterolemia
    • 13.6.3. Other Cardiovascular Disorders
  • 13.7. Market Attractiveness, by Indication
  • 13.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 13.8.1. Hospital Pharmacies
    • 13.8.2. Retail Pharmacies
    • 13.8.3. Online Pharmacies
  • 13.9. Market Attractiveness, by Distribution Channel
  • 13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.10.1. China
    • 13.10.2. Japan
    • 13.10.3. India
    • 13.10.4. Australia & New Zealand
    • 13.10.5. Rest of Asia Pacific
  • 13.11. Market Attractiveness Analysis
    • 13.11.1. By Drug Type
    • 13.11.2. By Modality
    • 13.11.3. By Indication
    • 13.11.4. By Distribution Channel
    • 13.11.5. By Country/Sub-region

14. Latin America PCSK9 Inhibitors Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Drug Type, 2020-2034
    • 14.2.1. Alirocumab
    • 14.2.2. Evolocumab
    • 14.2.3. Inclisiran
    • 14.2.4. Tafolecimab
  • 14.3. Market Attractiveness, by Drug Type
  • 14.4. Market Value Forecast, by Modality, 2020-2034
    • 14.4.1. Fully-humanized Monoclonal Antibodies
    • 14.4.2. siRNA
  • 14.5. Market Attractiveness, by Modality
  • 14.6. Market Value Forecast, by Indication, 2020-2034
    • 14.6.1. Primary Hyperlipidemia
    • 14.6.2. Familial Hyper Cholesterolemia
    • 14.6.3. Other Cardiovascular Disorders
  • 14.7. Market Attractiveness, by Indication
  • 14.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 14.8.1. Hospital Pharmacies
    • 14.8.2. Retail Pharmacies
    • 14.8.3. Online Pharmacies
  • 14.9. Market Attractiveness, by Distribution Channel
  • 14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.10.1. Brazil
    • 14.10.2. Mexico
    • 14.10.3. Rest of Latin America
  • 14.11. Market Attractiveness Analysis
    • 14.11.1. By Drug Type
    • 14.11.2. By Modality
    • 14.11.3. By Indication
    • 14.11.4. By Distribution Channel
    • 14.11.5. By Country/Sub-region

15. Middle East & Africa PCSK9 Inhibitors Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Drug Type, 2020-2034
    • 15.2.1. Alirocumab
    • 15.2.2. Evolocumab
    • 15.2.3. Inclisiran
    • 15.2.4. Tafolecimab
  • 15.3. Market Attractiveness, by Drug Type
  • 15.4. Market Value Forecast, by Modality, 2020-2034
    • 15.4.1. Fully-humanized Monoclonal Antibodies
    • 15.4.2. siRNA
  • 15.5. Market Attractiveness, by Modality
  • 15.6. Market Value Forecast, by Indication, 2020-2034
    • 15.6.1. Primary Hyperlipidemia
    • 15.6.2. Familial Hyper Cholesterolemia
    • 15.6.3. Other Cardiovascular Disorders
  • 15.7. Market Attractiveness, by Indication
  • 15.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 15.8.1. Hospital Pharmacies
    • 15.8.2. Retail Pharmacies
    • 15.8.3. Online Pharmacies
  • 15.9. Market Attractiveness, by Distribution Channel
  • 15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 15.10.1. GCC Countries
    • 15.10.2. South Africa
    • 15.10.3. Rest of Middle East & Africa
  • 15.11. Market Attractiveness Analysis
    • 15.11.1. By Drug Type
    • 15.11.2. By Modality
    • 15.11.3. By Indication
    • 15.11.4. By Distribution Channel
    • 15.11.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 16.2. Market Share Analysis, by Company (2023)
  • 16.3. Company Profiles
    • 16.3.1. Novartis AG
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. Regeneron Pharmaceuticals
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. Amgen Inc.
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. Innovent Bio
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. LIB Therapeutics
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. Shanghai Junshi Biosciences Co., Ltd.
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. Merck & Co., Inc.
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. AstraZeneca plc
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview